News for TruScreen Group Limited (TRU.AX)

Sydney-based biotech TruScreen Group (ASX: TRU) has launched a five-year cervical screening program in Vietnam using its artificial intelligence-enabled,

TruScreen Group Ltd recently launched a program aiming to screen 260,000 women for cervical cancer using its AI-enabled technology

Australian shares are expected to open this shorter trading week down as…

Cervical cancer screening device developer TruScreen Group (ASX: TRU) is set to undertake a major screening program with its technology in Vietnam. The

Medical device maker TruScreen Group (ASX:TRU) has announced its intention to launch a one-for-five rights issue to raise around NZ$2.2 million (A$2 million).

The ASX will open lower today. On Wall Street, losses picked up towards the end of the session with all major indices finishing lower

Kiwi medical device company TruScreen (ASX:TRU) surged 15% this morning after releasing the results of its successful clinical trial in China.

ASX small caps to watch on Tuesday 5 April, and highlights from Wall Street overnight. Stocks to watch are Quickstep and Truscreen.

ASX health stocks are down today. Resapp (ASX:RAP) said it has received TGA and CE mark approvals for its cough counting app.

Rhythm jumped 33% after it flagged the imminent commercialisation of its ColoSTAT technology.

Late bloomer IPOs include Australasian Gold (ASX:A8G), NexGen Energy (ASX:NXG), EP&T Global (ASX:EPX) and TruScreen (ASX:TRU).

12 ASX 10-baggers you may have missed, why Evergrande wobbles are a ‘game-changer’ for ASX miners, and a $127m potash failure.

TruScreen (ASX:TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening methods.

Closing Bell: ASX shrugs it off with another day of gains as investors clamour for more IPOs